Results 51 to 60 of about 524 (148)

Reduced Serum Urate Concentrations Despite Unchanged Allopurinol Dosing in Gout Patients Commenced on Dialysis: A Retrospective Chart Review

Nephrology, Volume 31, Issue 3, March 2026.
The study investigated allopurinol dosing practises and serum urate concentrations in gout patients with kidney failure following commencing dialysis. Results showed allopurinol dose was most commonly 100 mg, unadjusted upon commencing dialysis. However, serum urate concentrations significantly declined as patients commenced dialysis with more than 50%
Noha Kamel, Ronald Castelino, Daniel Wright, Kamal Sud, Surjit Tarafdar, Stephen Hughes, Sophie Stocker   +6 more
wiley   +1 more source

Some Adverse Reactions to Allopurinol May Be Mediated by Lymphocyte-Reactivity to Oxypurinol

, 1988
Six of 9 patients with previously documented adverse reactions to allopurinol exhibited transformation of their peripheral blood lymphocytes when these were exposed in vitro to the allopurinol metabolite, oxypurinol.
Hazelton, RA, Emmerson, BT, I. H. Frazer, B. T. Emmerson, R. A. Hazelton, Frazer, IH   +5 more
core   +1 more source

Mechanism for the Increased Permeability in Endothelial Monolayers Induced by Elastase

Mediators of Inflammation, 1994
The aim of this study was to investigate the mechanism for the increase in endothelial permeability induced by human neutrophil elastase (HNE). Pretreatment of bovine pulmonary artery endothelial cells (BPAEC) with HNE(0-30 μg/ml) for 1 h produced a ...
N. Suzuki, Y. Ishii, S. Kitamura
doaj   +1 more source

Serendipitous Symptom Control: Allopurinol for Spasticity in a Case of SPG4‐Linked Hereditary Spastic Paraplegia—A Case Report

Clinical Case Reports, Volume 14, Issue 1, January 2026.
Graphical representation of spasticity and medication changes. (A) Temporal course of lower limb spasticity measured by MAS scores. Following initiation of allopurinol 300 mg daily at baseline (red dashed line), there was a rapid and sustained improvement in spasticity from severe (MAS = 4) to mild (MAS = 1.8) over 12 months of follow‐up, represented ...
Ziad W. Elmezayen, Hossam Salameh, Asem Afana, Anwar Zahran   +3 more
wiley   +1 more source

Allopurinol Treatment Improves Cognitive Skills, Adaptive Behavior, and Biochemical Markers in Young Patients With Adenylosuccinate Lyase Deficiency

Journal of Inherited Metabolic Disease, Volume 48, Issue 6, November 2025.
ABSTRACT Adenylosuccinate lyase deficiency (ADSLD) is a rare neurological disorder characterized by psychomotor retardation, autistic behaviors, and seizures, with no specific treatment available. ADSL catalyzes the transformation of succinylaminoimidazole carboxamide ribotide (SAICAr) to AICAR, and succinyl‐AMP (S‐AMP) to AMP.
Bérangère Rousselot‐Pailley, Michaela Semeraro, Fabienne Marquant, Laurence Robel, Cyril Gitiaux, Anna Kaminska, Fanny Mochel, Prissile Bakouboula, Caroline Elie, Carole Hennequin, Irène Ceballos‐Picot, Sylvia Sanquer, Pascale de Lonlay   +12 more
wiley   +1 more source

Metabolic factors determining the effectiveness of hypouricemic treatment of gouty arthritis

Bolʹ, Sustavy, Pozvonočnik, 2018
Background. The treatment of some forms of arti­cular pathology with gout remains insufficiently effective, and often it’s impossible to achieve normal indicators of uricemia on the background of uric acid-normalizing medicines.
O.V. Syniachenko, D.M. Fedorov, M.V. Yermolaieva, V.V. Pylypenko   +3 more
doaj   +1 more source

Identifying Gene Predictors of Chemicals Linked With Breast Cancer: A Machine Learning Analysis of MCF7 Cellular Transcriptomic Screening Data

Environmental and Molecular Mutagenesis, Volume 66, Issue 8, Page 425-441, October 2025.
ABSTRACT Breast cancer is the most prevalent cancer in women and has been linked to exposure to environmental chemicals. However, many chemicals have not been evaluated for relationships with this outcome. In this study, we analyzed RNA sequencing data from human breast cancer‐derived MCF7 cells exposed to hundreds of individual chemicals.
Lauren E. Koval, Richard Judson, Julia E. Rager   +2 more
wiley   +1 more source

Oxipurinol

Drugs in R & D, 2004
Oxipurinol [alloxanthine, Oxyprim, oxypurinol] is the active metabolite of the only commercially available xanthine oxidase inhibitor, allopurinol. Oxipurinol is also a xanthine oxidase inhibitor. Oxipurinol is currently being developed by Cardiome Pharma.
openaire   +2 more sources

A Pharmacometric Workflow for Resolving Model Instability in Model Use‐Reuse Settings

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 10, Page 1544-1555, October 2025.
ABSTRACT The development of fit‐for‐purpose pharmacokinetic‐pharmacodynamic (PKPD) models based on clinical and pre‐clinical data is a critically important process in model informed drug development. This process is often hampered by modeling stability issues that are often multifactorial in nature and difficult to overcome, leading to protracted model
Stephen B. Duffull, Daniel F. B. Wright, Xiao Zhu, Xin Liu, Ahmed Abulfathi, Hailemichael Hishe   +5 more
wiley   +1 more source

Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates [PDF]

, 2022
BACKGROUND: Allopurinol, an xanthine oxidase (XO) inhibitor, is a promising intervention that may provide neuroprotection for neonates with hypoxic-ischemic encephalopathy (HIE).
ALBINO Study Group
core